

DAFTAR PUSTAKA

1. Parisi A, Porzio G, Pulcini F, Cannita K, Ficorella C, Mattei V, et al. What Is Known about Theragnostic Strategies in Colorectal Cancer. *Biomedicines*. 2021 Feb;9(2):140.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209–49.
3. Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. *CA Cancer J Clin*. 2023 May;73(3):233–54.
4. Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. *World J Gastrointest Surg*. 2023 Apr;15(4):495–519.
5. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. *Signal Transduct Target Ther*. 2020 Mar;5(1):22.
6. Barresi V. Colorectal cancer: From pathophysiology to novel therapeutic approaches. *Biomedicines*. 2021;9(12):10–2.
7. Bianchi G, Annicchiarico A, Morini A, Pagliai L, Crafa P, Leonardi F, et al. Three distinct outcomes in patients with colorectal adenocarcinoma and lymphovascular invasion: the good, the bad, and the ugly. *Int J Colorectal Dis*. 2021 Dec;36(12):2671–81.
8. Oh HH, Joo YE. Novel biomarkers for the diagnosis and prognosis of colorectal cancer. *Intest Res*. 2020 Apr;18(2):168–83.
9. Koncina E, Haan S, Rauh S, Letellier E. Prognostic and predictive molecular biomarkers for colorectal cancer: Updates and challenges. *Cancers (Basel)*. 2020;12(2):1–25.
10. Soleimani A, Pashirzad M, Avan A, Ferns GA, Khazaei M, Hassanian SM. Role of the transforming growth factor- β signaling pathway in the pathogenesis of colorectal cancer. *J Cell Biochem*. 2019 Jun;120(6):8899–907.
11. Maslankova J, Vecurkovska I, Rabajdova M, Katuchova J, Kicka M, Gayova M, et al. Regulation of transforming growth factor- β signaling as a therapeutic approach to treating colorectal cancer. *World J Gastroenterol*. 2022 Sep;28(33):4744–61.
12. Zhang M, Zhang YY, Chen Y, Wang J, Wang Q, Lu H. TGF- β Signaling

- and Resistance to Cancer Therapy. *Front Cell Dev Biol.* 2021;9(November):1–15.
13. Tzavlaki K, Moustakas A. TGF- β Signaling. *Biomolecules.* 2020 Mar;10(3):487.
 14. Soleimani A, Pashirzad M, Avan A, Ferns GA, Khazaei M, Hassanian SM. Role of the transforming growth factor- β signaling pathway in the pathogenesis of colorectal cancer. *J Cell Biochem.* 2019;120(6):8899–907.
 15. Mehrvarz Sarshekeh A, Katkhuda R, Verma A, Advani SM, Overman MJ, Maru DM, et al. Association of TGF- β expression with intratumoral infiltration of cytotoxic T lymphocytes in patients with microsatellite-stable colorectal cancer. *J Clin Oncol.* 2019 May;37(15_suppl):3577–3577.
 16. Peyravian N, Nobili S, Pezeshkian Z, Olfatifar M, Moradi A, Baghaei K, et al. Increased expression of vangl1 is predictive of lymph node metastasis in colorectal cancer: Results from a 20-gene expression signature. *J Pers Med.* 2021;11(2):1–22.
 17. Shi X, Yang J, Deng S, Xu H, Wu D, Zeng Q, et al. TGF- β signaling in the tumor metabolic microenvironment and targeted therapies [Internet]. Vol. 15, *Journal of Hematology and Oncology.* BioMed Central; 2022. 1–39 p. Available from: <https://doi.org/10.1186/s13045-022-01349-6>
 18. Stuelten CH, Zhang YE. Transforming Growth Factor- β : An Agent of Change in the Tumor Microenvironment. *Front Cell Dev Biol.* 2021;9(October):1–11.
 19. Tu Y, Han J, Dong Q, Chai R, Li N, Lu Q, et al. TGF- β 2 is a Prognostic Biomarker Correlated with Immune Cell Infiltration in Colorectal Cancer. *Medicine (Baltimore).* 2020 Nov;99(46):e23024.
 20. Zhang L, Deng Y, Liu S, Zhang W, Hong Z, Lu Z, et al. Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients. *BMC Cancer* [Internet]. 2023;23(1):1–10. Available from: <https://doi.org/10.1186/s12885-022-10416-7>
 21. Jiang HH, Zhang ZY, Wang XY, Tang X, Liu HL, Wang AL, et al. Prognostic significance of lymphovascular invasion in colorectal cancer and its association with genomic alterations. *World J Gastroenterol.* 2019 May;25(20):2489–502.
 22. Xu J, Lamouille S, Derynck R. TGF- β -induced epithelial to mesenchymal transition. *Cell Res.* 2009 Feb;19(2):156–72.
 23. Kim HJ, Choi G. Clinical Implications of Lymph Node Metastasis in

- Colorectal Cancer: Current Status and Future Perspectives. *Ann Coloproctol.* 2019 Jun;35(3):109–17.
24. Omeroglu S, Gulmez S, Uzun O, Senger AS, Bostanci O, Guven O, et al. Clinical significance of the histopathological metastatic largest lymph node size in colorectal cancer patients. *Front Oncol.* 2023;13(March):1–10.
 25. Lewis SL, Stewart KE, Garwe T, Sarwar Z, Morris KT. Node Harvest , Positivity , and Ratio in Colorectal Cancer. 2022;
 26. Xu X, Zhang C, Ni X, Wu J, Pan C, Wang S, et al. Population-based analysis on predictors for lymph node metastasis in T1 colon cancer. *Surg Endosc.* 2020 Sep;34(9):4030–40.
 27. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. *Histopathology.* 2020 Jan;76(2):182–8.
 28. Wong MCS, Huang J, Wong YY, Ko S, Chan VCW, Ng SC, et al. The Use of a Non-Invasive Biomarker for Colorectal Cancer Screening: A Comparative Cost-Effectiveness Modeling Study. *Cancers (Basel).* 2023;15(3).
 29. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2024;74(3):229–63.
 30. Yusuf I, Pardamean B, Baurley JW, Budiarto A, Miskad UA, Lusikooy RE, et al. Genetic risk factors for colorectal cancer in multiethnic Indonesians. *Sci Rep.* 2021 May;11(1):9988.
 31. Kementerian Kesehatan Republik Indonesia. *Profil Penyakit Tidak Menular 2016.* Jakarta; 2017. p. 56.
 32. Gargallo-Puyuelo CJ, Lanás Á, Carrera-Lasfuentes P, Ferrández Á, Quintero E, Carrillo M, et al. Familial Colorectal Cancer and Genetic Susceptibility: Colorectal Risk Variants in First-Degree Relatives of Patients With Colorectal Cancer. *Clin Transl Gastroenterol.* 2021 Feb;12(2):e00301.
 33. El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. Yuchi A, editor. *J Oncol.* 2021 Jul;2021:1–17.
 34. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis.

- Cancers (Basel). 2021 Apr;13(9):2025.
35. Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. *Cancers (Basel)*. 2022 Mar;14(7).
 36. Malki A, Elruz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements. *Int J Mol Sci*. 2021;22(1):1–24.
 37. Nguyen LH, Goel A, Chung DC. Pathways of Colorectal Carcinogenesis. *Gastroenterology* [Internet]. 2020;158(2):291–302. Available from: <https://doi.org/10.1053/j.gastro.2019.08.059>
 38. Marcellinaro R, Spoletini D, Grieco M, Avella P, Cappuccio M, Troiano R, et al. Colorectal Cancer: Current Updates and Future Perspectives. *J Clin Med*. 2024;13(1):1–12.
 39. Duan B, Zhao Y, Bai J, Wang J, Duan X, Luo X, et al. Colorectal Cancer: An Overview. In: *Gastrointestinal Cancers*. Exon Publications; 2022. p. 1–12.
 40. Chun HJ, Park SJ, Lim YJ, Song SY. Epidemiology and Prevention. I-3. Pathologic and Molecular Characteristics of Colorectal Cancer. In: *Gastrointestinal Cancer*. Singapore: Springer Nature Singapore; 2023. p. 233–7.
 41. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. *Ann Transl Med*. 2019;7(21):609–609.
 42. Ilie DS, Mitroi G, Păun I, Țenea-Cojan TȘ, Neamțu C, Totolici BD, et al. Pathological and immunohistochemical study of colon cancer. Evaluation of markers for colon cancer stem cells. *Rom J Morphol Embryol*. 2021;62(1):117–24.
 43. Jessup J, Goldberg RM, Asare EA, Benson AB. Colon and Rectum. In: *AJCC Cancer Staging Manual*. 8th ed. Chicago: Springer Nature; 2017. p. 251–86.
 44. Alzahrani S, Al Doghaither H, Al-Ghafari A. General insight into cancer: An overview of colorectal cancer (Review). *Mol Clin Oncol*. 2021 Nov;15(6):271.
 45. Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. *Therap Adv Gastroenterol*. 2020;13:1–11.
 46. Chen K, Collins G, Wang H, Toh JWT. Pathological Features and

- Prognostication in Colorectal Cancer. *Curr Oncol.* 2021 Dec;28(6):5356–83.
47. Kataoka M, Hirano Y, Ishii T, Kondo H, Asari M, Ishikawa S, et al. Impact of Lymphovascular Invasion in Patients With Stage II Colorectal Cancer: A Propensity Score-matched Study. *In Vivo (Brooklyn).* 2021;35(1):525–31.
 48. Özer L, Taşçı EŞ, Mutlu AU, Piyade B, Ramoğlu N, Ajredini M, et al. Intramural Component of Venous, Lymphatic, and Perineural Invasion in Colon Cancer: A Threat or an Illusion? *Balkan Med J.* 2022;39(6):436–43.
 49. Gao Z, Cao H, Xu X, Wang Q, Wu Y, Lu Q. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes. *World J Surg Oncol.* 2021 Dec;19(1):125.
 50. Dumont F, Muñoz MA, De Franco V, Wernert R, Verrielle V, Heyman M, et al. Significance of lymph node involvement in local recurrence of colorectal cancer. *J Surg Oncol.* 2019 Sep;120(4):722–8.
 51. Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, et al. TGF- β signaling in health, disease, and therapeutics. *Signal Transduct Target Ther.* 2024;9(1).
 52. Goebel EJ, Hart KN, McCoy JC, Thompson TB. Structural biology of the TGF β family. *Exp Biol Med.* 2019 Dec;244(17):1530–46.
 53. Aashaq S, Batoool A, Mir SA, Beigh MA, Andrabi KI, Shah ZA. TGF- β signaling: A recap of SMAD-independent and SMAD-dependent pathways. *J Cell Physiol.* 2022 Jan;237(1):59–85.
 54. Massagué J, Sheppard D. TGF- β signaling in health and disease. *Cell.* 2023;186(19):4007–37.
 55. Chung JYF, Chan MKK, Li JSF, Chan ASW, Tang PCT, Leung KT, et al. TGF- β Signaling: From Tissue Fibrosis to Tumor Microenvironment. *Int J Mol Sci.* 2021 Jul;22(14):7575.
 56. Itatani Y, Kawada K, Sakai Y. Transforming growth factor- β signaling pathway in colorectal cancer and its tumor microenvironment. *Int J Mol Sci.* 2019;20(23).
 57. Waldner MJ, Neurath MF. TGF β and the Tumor Microenvironment in Colorectal Cancer. *Cells.* 2023;12(8):1–14.
 58. Xue VW, Chung JYF, Córdoba CAG, Cheung AHK, Kang W, Lam EWF, et al. Transforming Growth Factor- β : A Multifunctional Regulator of Cancer Immunity. *Cancers (Basel).* 2020 Oct;12(11):3099.

59. Baba AB, Rah B, Bhat GR, Mushtaq I, Parveen S, Hassan R, et al. Transforming Growth Factor-Beta (TGF- β) Signaling in Cancer-A Betrayal Within. *Front Pharmacol*. 2022;13(February):1–16.
60. Tie Y, Tang F, Peng D, Zhang Y, Shi H. TGF-beta signal transduction: biology, function and therapy for diseases. *Mol Biomed* [Internet]. 2022;3(1). Available from: <https://doi.org/10.1186/s43556-022-00109-9>
61. Li Y, Chen Z, Han J, Ma X, Zheng X, Chen J. Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer. *Front Oncol*. 2022;12(February):1–13.
62. Mizuno R, Kawada K, Itatani Y, Ogawa R, Kiyasu Y, Sakai Y. The role of tumor-associated neutrophils in colorectal cancer. *Int J Mol Sci*. 2019;20(3):1–14.
63. Sieminska I, Baran J. Myeloid-Derived Suppressor Cells in Colorectal Cancer. *Front Immunol*. 2020;11(August):1–10.
64. Dahmani A, Delisle JS. TGF- β in T Cell Biology: Implications for Cancer Immunotherapy. *Cancers (Basel)*. 2018 Jun;10(6):194.
65. Li X, Wu Y, Tian T. TGF- β Signaling in Metastatic Colorectal Cancer (mCRC): From Underlying Mechanism to Potential Applications in Clinical Development. *Int J Mol Sci*. 2022;23(22).
66. Sabbadini F, Bertolini M, De Matteis S, Mangiameli D, Contarelli S, Pietrobono S, et al. The multifaceted role of TGF- β in gastrointestinal tumors. *Cancers (Basel)*. 2021;13(16):1–24.
67. Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. *Nat Rev Immunol* [Internet]. 2021;21(10):653–67. Available from: <http://dx.doi.org/10.1038/s41577-021-00534-x>
68. Sakai E, Nakayama M, Oshima H, Kouyama Y, Niida A, Fujii S, et al. Combined mutation of *Apc*, *Kras*, and *Tgfbr2* effectively drives metastasis of intestinal cancer. *Cancer Res*. 2018;78(5):1334–46.
69. Gough NR, Xiang X, Mishra L. TGF- β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer. *Gastroenterology* [Internet]. 2021;161(2):434-452.e15. Available from: <https://doi.org/10.1053/j.gastro.2021.04.064>
70. Zeng C, He R, Dai Y, Lu X, Deng L, Zhu Q, et al. Identification of TGF- β signaling-related molecular patterns, construction of a prognostic model, and prediction of immunotherapy response in gastric cancer. *Front Pharmacol*. 2022 Nov;13.

71. Liao J, Liu Q, Chen J, Lu Z, Mo H, Jia J. A risk score model based on TGF- β pathway-related genes predicts survival, tumor microenvironment and immunotherapy for liver hepatocellular carcinoma. *Proteome Sci* [Internet]. 2022;20(1):1–13. Available from: <https://doi.org/10.1186/s12953-022-00192-4>
72. Chandra R, Karalis JD, Liu C, Murimwa GZ, Park JV, Heid CA, et al. The colorectal cancer tumor microenvironment and its impact on liver and lung metastasis. *Cancers (Basel)*. 2021;13(24):1–30.
73. Wu D, Ding Y, Wang T, Cui P, Huang L, Min Z, et al. Significance of Tumor-Infiltrating Immune Cells in the Prognosis of Colon Cancer. *Onco Targets Ther*. 2020 May;Volume 13:4581–9.
74. Niknami Z, Muhammadnejad A, Ebrahimi A, Harsani Z, Shirkoohi R. Significance of e-cadherin and vimentin as epithelial-mesenchymal transition markers in colorectal carcinoma prognosis. *EXCLI J*. 2020;19:917–26.
75. Hosseini S, Rejali L, Pezeshkian Z, Malekian M, Fatemi N, Peyravian N, et al. Oncogenic Role of Connective Tissue Growth Factor Is Associated with Canonical TGF- β Cascade in Colorectal Cancer. *Genes (Basel)*. 2022;13(4).
76. Matsuoka T, Yashiro M. The Role of the Transforming Growth Factor- β Signaling Pathway in Gastrointestinal Cancers. *Biomolecules*. 2023 Oct;13(10):1551.
77. Adelia Rachmita P, Hilbertina N, Yenita Y, Agus S, Suchitra A, Yetti H. Correlation of CD133 Expression with Tumor Location and Lymph Node Involvement in Colorectal Carcinoma. *Maj Patol Indones*. 2023;32(3):678–83.
78. Sugiarto S, Nurfitriana A, Marindawati M. Relationship between Age and Sex with Histopathological Differentiation of Colorectal Adenocarcinoma. *Muhammadiyah Med J*. 2022;3(2):67.
79. Factors R. *Colorectal Cancer: Epidemiology, Risk Factors, and Prevention*. 2024;
80. Cho MY, Siegel DA, Demb J, Richardson LC, Gupta S. Increasing Colorectal Cancer Incidence Before and After Age 50: Implications for Screening Initiation and Promotion of “On-Time” Screening. *Dig Dis Sci* [Internet]. 2022;67(8):4086–91. Available from: <https://doi.org/10.1007/s10620-021-07213-w>
81. White A, Ironmonger L, Steele RJC, Ormiston-Smith N, Crawford C,

- Seims A. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK. *BMC Cancer*. 2018;18(1):1–11.
82. Dewi NNA, Widya Suksmarini NMP. Metilasi DNA dalam Perkembangan Kanker Kolorektal. *Intisari Sains Medis*. 2018;9(2):124–30.
83. Wang H, Yuan Z, Wang S, Pang W, Wang W, Liu X, et al. The comparison of risk factors for colorectal neoplasms at different anatomical sites. *Int J Colorectal Dis* [Internet]. 2023;38(1):1–11. Available from: <https://doi.org/10.1007/s00384-022-04296-3>
84. Minhajat R, Benyamin AF, Miskad UA. The Relationship Between Histopathological Grading and Metastasis in Colorectal Carcinoma Patients. 2020;5(2):51–60.
85. Tsabit SS, Trianto HF, Pratiwi SE, Hartono H. Clinicopathological Profile of Colorectal Adenocarcinoma in the Anatomical Pathology Laboratory of Dr. Soedarso Hospital Pontianak. *Indones J Cancer*. 2023;17(4):292.
86. Liang J wang, Gao P, Wang Z ning, Song Y xi, Xu Y ying, Wang M xian, et al. The Integration of Macroscopic Tumor Invasion of Adjacent Organs into TNM Staging System for Colorectal Cancer. *PLoS One*. 2012;7(12).
87. Sert Bektaş S, Inan Mamak G, Çiriş IM, Bozkurt KK, Kapucuoğlu N. Kolorektal karsinomlarda tümör tomurcuklanması. *Türk Patoloji Dergisi/Turkish J Pathol*. 2012;28(1):61–6.
88. Polyps CC, Be C, Early F, Cancer C, Tests S, Signs CC, et al. Colorectal Cancer Early Detection , Diagnosis , and Staging Can Colorectal Polyps and Cancer Be Found Early ? 2017;1–40.
89. Kuo YT, Tsai WS, Hung HY, Hsieh PS, Chiang SF, Lai CC, et al. Prognostic value of regional lymph node involvement in patients with metastatic colorectal cancer: palliative versus curative resection. *World J Surg Oncol*. 2021;19(1):1–9.
90. Lee H, Yoo SY, Park IJ, Hong SM, Lim SB, Yu CS, et al. The Prognostic Reliability of Lymphovascular Invasion for Patients with T3N0 Colorectal Cancer in Adjuvant Chemotherapy Decision Making. *Cancers (Basel)*. 2022;14(12):1–13.
91. Akagi Y, Adachi Y, Ohchi T, Kinugasa T, Shirouzu K. Prognostic impact of lymphatic invasion of colorectal cancer: A single-center analysis of 1,616 patients over 24 years. *Anticancer Res*. 2013;33(7):2965–70.
92. Chen X lin, Chen Z qun, Zhu S lian, Liu T wen, Wen Y, Su Y sheng, et al. Prognostic value of transforming growth factor-beta in patients with

- colorectal cancer who undergo surgery: A meta-analysis. *BMC Cancer*. 2017;17(1):1–11.
93. Pellatt AJ, Mullany LE, Herrick JS, Sakoda LC, Wolff RK, Samowitz WS, et al. The TGF β -signaling pathway and colorectal cancer: Associations between dysregulated genes and miRNAs. *J Transl Med* [Internet]. 2018;16(1):1–22. Available from: <https://doi.org/10.1186/s12967-018-1566-8>
94. De Summa S, Danza K, Pilato B, Matera G, Fasano R, Calabrese A, et al. A promising role of tgf- β pathway in response to regorafenib in metastatic colorectal cancer: A case report. *Med*. 2021;57(11):1–9.
95. Itoh F, Watabe T. TGF- β signaling in lymphatic vascular vessel formation and maintenance. *Front Physiol*. 2022;13(December):1–7.
96. Bhat IP, Rather TB, Maqbool I, Rashid G, Akhtar K, Bhat GA, et al. Connective tissue growth factor expression hints at aggressive nature of colorectal cancer. *World J Gastroenterol*. 2022;28(5):547–69.
97. Fujimoto N, Dieterich LC. Mechanisms and clinical significance of tumor lymphatic invasion. *Cells*. 2021;10(10).
98. Fasano M, Pirozzi M, Miceli CC, Cocule M, Caraglia M, Boccellino M, et al. TGF- β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities. *Int J Mol Sci*. 2024;25(13).

